<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03316118</url>
  </required_header>
  <id_info>
    <org_study_id>STU#:00204116</org_study_id>
    <nct_id>NCT03316118</nct_id>
  </id_info>
  <brief_title>A Comparison of Analgesic Efficacy of Ultrasound-Guided Genicular Nerve Block Versus Saline Injection for Total Knee Replacement</brief_title>
  <official_title>A Comparison of Analgesic Efficacy of Ultrasound-Guided Genicular Nerve Block Versus Saline Injection for Total Knee Replacement: a Prospective, Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Do ultrasound-guided genicular nerve blocks with 0.5% bupivacaine provide improved knee&#xD;
      analgesia for patients recovering from total knee replacement surgery compared to saline&#xD;
      injection?&#xD;
&#xD;
      Hypotheses:&#xD;
&#xD;
      The investigators hypothesize that the combination of ultrasound-guided adductor canal block&#xD;
      (ACB) and genicular nerve block will achieve lower opioid consumption and therefore lead to&#xD;
      decreased systemic side effects and improved overall satisfaction compared to&#xD;
      ultrasound-guided saline injection for patients undergoing minimally invasive elective total&#xD;
      knee arthroplasty (TKA).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low Enrollment&#xD;
  </why_stopped>
  <start_date type="Actual">October 5, 2017</start_date>
  <completion_date type="Actual">June 21, 2021</completion_date>
  <primary_completion_date type="Actual">June 21, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-operative opioid consumption during the hospital stay</measure>
    <time_frame>21 days after surgery</time_frame>
    <description>Post-operative opioid consumption measured in morphine equivalents during the hospital stay.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain scores in the knee at rest and during activity recorded every 6 hours up to discharge</measure>
    <time_frame>21 days after surgery</time_frame>
    <description>Pain scores in the knee at rest and during activity. This will be measured every 6 hours up to discharge with the visual analog scale where 0 equals no pain and 10 equals excruciating pain. Low pain scores are considered a better outcome than high pain scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall global pain score recorded every 6 hours up to discharge</measure>
    <time_frame>21 days after surgery</time_frame>
    <description>Overall global pain score. This will be measured every 6 hours up to discharge with the visual analog scale where 0 equals no pain and 10 equals excruciating pain. Low pain scores are considered a better outcome than high pain scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall pain burden for the first 36 hours</measure>
    <time_frame>36 hours after surgery</time_frame>
    <description>Pain burden is defined as the area under the visual analog scale for pain over the first 36 hours and will be calculated using the trapezoidal method. Time to report first pain and overall patient satisfaction between groups will be compared using the Kruskal-Wallis H test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid related side effects</measure>
    <time_frame>21 days after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to physical therapy milestones</measure>
    <time_frame>21 days after surgery</time_frame>
    <description>active straight leg raise, time until patient first gets out of bed, ambulation about the hospital room with or without assistance, ambulating 100 feet and ability to climb stairs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospitalization</measure>
    <time_frame>21 days after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readmission to the hospital or emergency room visit for evaluation during study</measure>
    <time_frame>1 year after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Postoperative Pain</condition>
  <condition>Total Knee Arthroplasty</condition>
  <condition>Nerve Block</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient will receive genicular nerve block with bupivacaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patient will receive normal saline as the nerve block</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bupivacaine</intervention_name>
    <description>Group 1 will receive genicular nerve block using bupivacaine</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>saline</intervention_name>
    <description>Group 2 will receive genicular nerve block using normal saline</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants 40 to 85 years old who are presenting for minimally invasive total knee&#xD;
             arthroplasty under spinal anesthesia and are candidates for peripheral nerve blocks.&#xD;
&#xD;
          -  Minimally invasive is defined as custom modified instrumentation, a quadriceps sparing&#xD;
             arthrotomy that does not extend beyond 1cm proximal to the patella and surgical&#xD;
             techniques that focus on soft tissue protection.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient refusal&#xD;
&#xD;
          -  American Society of Anesthesiologists physical status classification of 4 or higher&#xD;
&#xD;
          -  Pre-existing neuropathy in the femoral or sciatic distribution&#xD;
&#xD;
          -  Coagulopathy&#xD;
&#xD;
          -  Infection at the site&#xD;
&#xD;
          -  Chronic opioid use (greater than 3 months)&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Medical conditions limiting physical therapy participation&#xD;
&#xD;
          -  Any other contra-indication to regional anesthesia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antoun M Nader, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 5, 2017</study_first_submitted>
  <study_first_submitted_qc>October 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2017</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Antoun Nader</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>anesthesiology</keyword>
  <keyword>pain</keyword>
  <keyword>arthroplasty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

